U.S. FTC Sees Red Flags In Studies Conducted Overseas To Support Supplement Claims
This article was originally published in PharmAsia News
Executive Summary
The Federal Trade Commission is wary of studies conducted overseas used to substantiate claims for supplements, says Richard Cleland, assistant director of advertising practices